Correction: The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow.

Lange, Andrzej; Jaskula, Emilia; Lange, Janusz; Dworacki, Grzegorz; Nowak, Dorota; Simiczyjew, Aleksandra; Mordak-Domagala, Monika; Sedzimirska, Mariola · PLoS One · 2018

Where this comes from

Record sourced from PubMed, PMID 30521628.
Also identified by DOI 10.1371/journal.pone.0209108 and PMC identifier 6283549.
No licence information is recorded for this record.
Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0190525.].

Read the full text

View on PubMed · Publisher (DOI)